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Cardiovascular diseases remain the most common cause 
of death in Western countries and their prevalence in the 
general population increases progressively with age, reaching 
more than 60% in subjects older than 60 years (1). This is at 
least in part due to a progressive impairment of the cellular 
processes regulating cardiac and vascular homeostasis, 
finally leading to the development of cardiovascular 
abnormalities (2). In addition, the molecular mechanisms 
that protect the heart against stress are downregulated 
by aging, making the myocardium more susceptible to 
injury (2). It is therefore important to find new therapeutic 
targets to reduce cardiovascular aging and protect the aged 
myocardium from stress. 
Autophagy is a mechanism of intracellular degradation 
through lysosomes characterized by the presence of 
double membrane vesicles called autophagosomes (2,3). 
Increasing lines of evidence suggest that autophagy plays 
an important role in maintaining cardiac homeostasis. 
Autophagy is downregulated in the heart during aging, and 
downregulation of autophagy plays a causative role in the 
progression of aging in the heart (2,4). Furthermore, we 
and others have shown that downregulation of autophagy 
during pressure overload (5,6), post-myocardial infarction 
cardiac remodeling (7) and metabolic syndrome (8,9) 
contributes to the progression of cardiac dysfunction and 
ischemic injury. On the other hand, excessive activation of 
autophagy during the acute phase of myocardial infarction 
or ischemia/reperfusion may be detrimental (10). Thus, 
identifying molecular interventions to control the activity 
of autophagy is important and may lead to the development 
of a novel treatment for heart disease, especially in elderly 
patients. 
Using high-throughput screening based on the 
fluorescence-activated cell sorting-based detection of 
GFP-LC3 protein and library screening, Gupta et al. 
identified miR-22 as a strong inhibitor of autophagy in 
cardiomyocytes (11). The authors showed that miR-22 
inhibits the reduction in GFP-LC3 signal in response to 
starvation, an established stimulus for autophagy. This 
screening method is based on the fact that the GFP-LC3 
signal is attenuated when GFP-LC3 autophagosomes move 
from the cytosol to lysosomes (12). Thus, it is a convenient 
and reliable method to evaluate the level of autophagic 
flux from autophagosome formation to autolysosome 
formation. A cautionary note, however, is that the results of 
this method are easily affected by conditions that alter the 
intensity of the GFP signal through autophagy-independent 
mechanisms. Thus, the authors could have conducted 
more extensive validation regarding how miR-22 affects 
autophagic flux in cardiomyocytes throughout the study. 
Nevertheless, this is a fascinating way to identify effective 
modifiers of autophagy in cardiomyocytes and, by extending 
this approach to small molecules, it may be possible to 
identify novel interventions for heart failure patients.
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Gupta et al. demonstrated that miR-22 expression 
progressively increases in the mouse heart during aging (11). 
miR-22 inhibition by locked nucleic acid-based anti-
miR-22 (LNA-anti-miR-22) significantly attenuated 
cardiac remodeling in old mice subjected to permanent 
coronary artery ligation, reducing left ventricular dilation 
and improving systolic function. In contrast, the beneficial 
effects of miR-22 inhibition were not obvious in young 
mice with chronic myocardial infarction. Thus, miR-22 
upregulation in the aged heart appears to impair adaptation 
to chronic myocardial infarction. miR-22 inhibition limits 
senescence-induced cardiomyocyte hypertrophy in vitro. 
Therefore, the cardioprotective effects of pharmacological 
miR-22 inhibition in the mouse heart may be dependent 
on its protective actions in cardiomyocytes. However, since 
miR-22 also induces senescence in cardiac fibroblasts, 
increasing their migratory capacity (13), it is possible that 
miR-22 inhibition may also elicit beneficial functions 
through the other cell types in the heart. 
miR-22 appeared to be responsible for the reduction of 
autophagy in the old myocardium. The increase in cardiac 
miR-22 levels during aging was paralleled by a progressive 
decline in myocardial autophagy. Importantly, miR-22 
inhibition appears to rescue autophagy in aging hearts (11). 
miR-22 may have autophagy-independent actions, and 
thus, the causative involvement of autophagy in mediating 
the salutary actions of miR-22 inhibition remains to be 
demonstrated. Nevertheless, the fact that miR-22 inhibition 
can stimulate autophagy in the aging heart is attractive. 
Restoring the level of autophagy has been shown to be 
salutary in some cardiovascular conditions. For example, 
genetic inhibition of the serine-threonine kinase MST1, 
a stress activated kinase known to inhibit autophagy, 
reduces remodeling caused by chronic ischemia through 
the activation of autophagy (7). In addition, administration 
of spermidine, a natural polyamine compound, extended 
life span in mice and reduced cardiac hypertrophy and 
diastolic dysfunction induced by aging. These effects were 
found to be dependent on the capacity of spermidine to 
activate autophagy through the inhibition of the histone 
acetyltransferase p300. In fact, the cardioprotective effects 
of spermidine were lost in mice with genetic disruption of 
autophagy (4). 
Other miRs also regulate autophagy in the heart. 
Thum’s group elegantly showed that miRNA-212/132 
inhibits autophagy in cardiomyocytes by targeting 
FoxO3a. Pharmacological inhibition of miR-132 reduced 
cardiac hypertrophy and heart failure induced by pressure 
overload (14). In addition, exosome-mediated miR-145 
administration was found to reduce ischemic injury by 
activating autophagy (15). Thus, targeting these miRNAs 
could represent a new avenue of exploration in the 
development of novel interventions to treat heart failure in 
elderly patients. 
miR-22a plays a dual role in the heart, performing 
both physiological and maladaptive functions. Mice with 
either systemic or cardiac-specific miR-22 gene deletion 
do not develop compensatory hypertrophy in response 
to isoproterenol treatment and display increased cardiac 
dilation and dysfunction with respect to control mice (16). 
Similarly, systemic miR-22 knockout mice were found to 
develop cardiac dilation and dysfunction in response to 
pressure overload (17). These effects were associated with a 
downregulation of Serca2a expression and with sarcomere 
disarray. Interestingly, however, miR-22 gain of function 
also appears to be maladaptive. Mice with cardiac-specific 
miR-22 overexpression develop cardiac hypertrophy and 
dysfunction, and these deleterious effects are associated 
with impaired calcium handling and reduced expression 
of PPARα, SIRT1 and PGC-1α (18). Thus, it is likely that 
proper cardiac function requires that miR-22 expression 
levels remain within a relatively narrow physiological range. 
The molecular mechanism by which miR-22 inhibits 
autophagy has not yet been fully elucidated. miR-22 was 
found to inhibit autophagy in cardiomyocytes by reducing 
the expression of PPARα (11). However, other mechanisms 
may also be involved in the inhibitory effects of miR-22 
on autophagy. It was previously demonstrated that miR-
22 reduces the expression of PTEN, a negative regulator 
of the AKT pathway, in cardiomyocytes (19). This suggests 
that miR-22 may also suppress autophagy through 
activation of AKT, which may, in turn, activate the kinase 
mTOR, a negative regulator of the autophagic process (20). 
Since miR-22 affects cardiac function through multiple 
mechanisms, it is also possible that the inhibition of 
autophagy is indirectly mediated through other functional 
targets of miR-22, such as the mitochondrial dysfunction 
and metabolic remodeling observed in hearts following 
myocardial infarction. Future studies are warranted to test 
this possibility. 
Aside from autophagy, other mechanisms may also 
underlie the beneficial cardiac effects of pharmacological 
miR-22 inhibition (Figure 1). Inhibition of the AKT/
mTOR pathway may be one of these mechanisms, since 
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there is a large body of evidence demonstrating that chronic 
and deregulated activation of mTOR is detrimental during 
cardiac stress, whereas its pharmacological inhibition is 
protective (20). SIRT1 was also found to be a target of 
miR-22 (18), so that activation of SIRT1 may represent 
another mechanism through which miR-22 inhibition may 
reduce age-related cardiac diseases. We previously found 
that SIRT1 reduces cardiac aging and confers resistance 
to oxidative stress (21), and SIRT1 has also been shown 
to limit ischemic injury (22). Finally, miR-22 inhibition 
may upregulate PGC-1α, another miR-22 target. PGC-1α 
controls mitochondrial biogenesis and its upregulation may 
favor mitochondrial turnover and proper mitochondrial 
function, which are usually impaired in the old heart (2). 
In this regard, mice with PGC-1α gene deletion display an 
impaired energy state and develop contractile dysfunction 
during aging (23).
One of the most remarkable results of the study by 
Gupta et al. is the demonstration that miR-22 dysregulation 
is relevant to human disease. In fact, the authors found 
that high circulating levels of miR-22 are associated with a 
higher cardiovascular mortality in patients affected by heart 
failure (11). Future studies are warranted to investigate 
whether miR-22 can be used as a biomarker to monitor the 
efficacy of pharmacological therapy in heart failure patients. 
It will be important to evaluate whether the pharmacological 
inhibition of miR-22 ameliorates symptoms and outcomes 
in these subjects. Of note, atorvastatin was previously seen to 
reduce the expression of miR-22 in cardiomyocytes (24) and 
was also shown to ameliorate heart failure in patients (25). 
In conclusion, Gupta et al. provided compelling 
results indicating that miR-22 upregulation in the heart 
is responsible for the reduction of autophagy and the 
increased susceptibility to stress during aging. miR-22 
may be considered as a potential therapeutic target for the 
treatment of age-related diseases (Figure 1). 
Acknowledgements






PTEN SIRT1 PPARα PGC-1α
Oxidative stressCM hypertrophy Mitochondrial function
AUTOPHAGY
Energy status
Figure 1 miR-22 promotes age-related cardiac abnormalities. Schematic representation of the molecular mechanisms through which miR-
22 promotes age-related cardiac abnormalities. Autophagy inhibition appears to play a major role in the development of these abnormalities. 
CM, cardiomyocyte; PTEN, phosphatase and tensin homolog; PPARα, peroxisome proliferator-activated receptor α; PGC-1α, peroxisome 
proliferator-activated receptor gamma coactivator-related protein 1α.
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